Advertisement

Advertisement

Anthony Letai, MD, PhD, Sworn in as New NCI Director

Anthony Letai, MD, PhD, was sworn in on September 29 as Director of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), by Health and Human Services Secretary Robert F. Kennedy, Jr.

 

Thyroid Cancer

FDA Removes Vandetanib REMS Program

On September 25, the U.S. Food and Drug Administration (FDA) removed the Risk Evaluation and Mitigation Strategies (REMS) program for vandetanib, according to an announcement from the agency.

 

Breast Cancer

$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening

The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening and reducing unnecessary callbacks and anxiety for patients. 

 


Advertisement
Prostate Cancer

Prostate Cancer: Radiopharmaceutical Plus SBRT Delays Progression in Patients With Limited Metastatic Disease

A new clinical trial found that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation compared with radiation alone.

 

Head and Neck Cancer

Addition of Xevinapant to Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck

In a phase III trial (TrilynX) reported in the Journal of Clinical Oncology, Bourhis et al found that the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) to platinum-based chemoradiotherapy did not improve event-free survival in patients with unresected locally advanced squamous cell carcinoma of the head and neck.

 

Advertisement
Advertisement





More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

James R. Doty, MD, Pioneer in Neurosurgical Innovation and the Scientific Study of Compassion, Dies at 69

James R. Doty, MD James R. Doty, MD, Clinical Professor of Neurosurgery at Stanford University and a pioneer in both neurosurgical innovation and the scientific study of compassion, died on July 16, 2025. He was 69. Dr. Doty’s death occurred after prolonged hospitalization for medical...

Advertisement

Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia

Treatment with obecabtagene autoleucel was the focus of the phase Ib/II multicenter FELIX study of more than 100 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).1 The initial report in 2024 revealed a rate of complete remission or complete remission with incomplete...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

ASCO Remembers Past President Harvey M. Golomb, MD, FASCO

ASCO is deeply saddened by the loss of past president Harvey M. Golomb, MD, FASCO, a pioneer in the study of interferon as cancer treatment. Dr. Golomb passed away on August 20, 2025; he was 82. From the beginning of his medical career, Dr. Golomb was a committed member of ASCO. He joined the...

Prostate Cancer

New NIH-Funded Study Identifies Urine-Based Assay for Prostate Cancer

Researchers have developed a novel method to test for prostate cancer using biomarkers present in urine. This approach may significantly reduce the need for invasive, often painful biopsies, the researchers said in a statement. The study, which was funded in part by the National Institutes of...

Cytogenetic Remission Linked to Improved Survival in Patients With AML

Patients with acute myeloid leukemia (AML) who achieve cytogenetic remission may have better survival outcomes than patients with new or sustained cytogenetic abnormalities, according to findings from a study published in the American Journal of Hematology.  The study elucidated how cytogenetic...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR

ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The ASCO-sponsored TAPUR study is a...

Advertisement

Medicare Telehealth Flexibilities and CMS Operations During Government Shutdown

The U.S. government shut down on October 1 after lawmakers were unable to reach a funding agreement. The date also marked the deadline to extend the Medicare telehealth flexibilities that have been in place since the COVID-19 public health emergency (PHE). As such, telehealth flexibilities have...

ASCO Post X Feed
Social Media Hub by Everwall